Therapy advances of non-biological artificial liver_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZOU Long , LIU Hong , MA Linjie , CHEN Xiao ,  CHEN Gang

Department of Hepatobiliary Surgery, Affiliated Calmette Hospital of Kunming Medical University, Kunming 650011, P.R.China;

Corresponding?author：

CHEN Gang, Email: kmcg123@163.com

Keywords：

artificial liver; liver function failure; therapy; progress

DOI：

10.7507/1007-9424.201607025

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize present situation and development of non-biological artificial liver. Method The related literatures about artificial liver treatment in recent years were reviewed. Results The current artificial liver which applied to clinic mainly are non-biological artificial liver, including plasma exchange, hemodialysis, hemofiltration, bilirubin adsorption, hemoperfusion, molecular adsorption recycling, etc. Because of the individual clinical cases, the individualized requirements for treatment are put forward. Single treatment of non-biological artificial liver is often unable to satisfy the individualized requirements, combined the advantages of each treatment so as to maximum therapeutic effect for patients has become a trend. Conclusion Combined treatment of non-biological artificial liver is superior to single treatment, individual treatment concept should be carried out in whole process of treatment.

Citation： ZOU Long, LIU Hong, MA Linjie, CHEN Xiao, CHEN Gang. Therapy advances of non-biological artificial liver. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(5): 634-637. doi: 10.7507/1007-9424.201607025 Copy

1.	?宋傳芳, 劉冰熔. 急性肝衰竭的綜合治療. 世界華人消化雜志, 2012, 20(33): 3237-3243.
2.	中華醫學會感染病學分會肝衰竭與人工肝學組, 中華醫學會肝病學分會重型肝病與人工肝學組. 肝衰竭診治指南(2012 年版). 實用肝臟病雜志, 2013, 16(3): 210-216.
3.	Rademacher S, Oppert M, J?rres A. Artificial extracorporeal liver support therapy in patients with severe liver failure. Expert Rev Gastroenterol Hepatol, 2011, 5(5): 591-599.
4.	Kiley JE, Welch hf, Pender JC,et al. Removal of blood ammonia by hemodialysis. Proc Soc Exp Biol Med, 1956, 91(3): 489-490.
5.	Norman JC, Saravis CA, Brown ME,et al. Immunological observations in clinical heterologous (xenogeneic) liver perfusions. Surgery, 1966, 60: 179-190.
6.	Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future. Gut, 2009, 58(12): 1690-1702.
7.	Millis JM, Losanoff JE. Technology insight: liver support systems. Nat Clin Pract Gastroenterol Hepatol, 2005, 9(2): 398-405.
8.	Onodera K, Sakata H, Yonekaua M,et al. Artificial liver support at present and in the future. J Artif Organs, 2006, 9(1): 17-28.
9.	Aron J, Agarwal B, Daven Port A. Extracorporal support for patients with acute on chronic liver failure . Exp Rev Med Dev, 2016, 10(2): 390-405.
10.	Li LJ, Zhang YM, Liu XL,et al. Artificial liver support system in China: a review over the last 30 years. Ther Apher Dial, 2006, 10(2): 160-167.
11.	Li LJ, Liu XL, Xu XW,et al. Comparison of plasma exchange with different membrane pore sizes in the treatment of severe viral hepatitis. Ther Apher Dial, 2005, 9(5): 396-401.
12.	Larsen FS, Hansen BA, J?rgensen LG,et al. High-volume plasmapheresis and acute liver transplantation in fulminant hepatic failure. Transplant Proc, 1994, 26(3): 1788.
13.	Pless G. Artificial and bioartifical liver support. Organogenesis, 2007, 3(1): 20-24.
14.	鄒和群, 劉新宇. 加強血漿凈化技術臨床推廣應用研究. 中華臨床醫師雜志(電子版), 2015, 9(17): 3165-3167.
15.	程芝靈, 孫桂香, 林輝, 等. 血漿置換治療肝衰竭臨床療效和安全性的 Meta 分析. 中國循證醫學雜志, 2015, 15(6): 664-671.
16.	楊文龍, 孫水林, 周錫進, 等. 終末期肝病模型評分與 Child-Turcotte-Pugh 分級對非生物型人工肝治療乙型肝炎相關性肝衰竭患者預測價值的研究. 中華危重癥醫學雜志(電子版), 2016, 9(1): 22-27.
17.	中華傳染病與寄生蟲病學會人工肝學組. 人工肝支持系統治療的操作指南. 中華肝臟病雜志, 2002, 10(5): 329-333.
18.	曾義嵐, 陳竹, 王麗, 等. 人工肝聯合抗病毒治療乙型肝炎相關慢加急性肝功能衰竭患者的療效及影響因素分析. 中國肝臟病雜志(電子版), 2015, 7(4): 26-30.
19.	Patzer JF 2nd, Bane SE. Bound solute dialysis. ASAIO J, 2003, 49(3): 271-281.
20.	Jalan R, Sen S, Steiner C,et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol, 2003, 38(1): 24-31.
21.	Inderbitzin D, Muggli B, Ringger A,et al. Molecular absorbent recirculating system for the treatment of acute liver failure in surgical patients. J Gastrointest Surg, 2005, 9(8): 1155-1162.
22.	Olin P, Hausken J, Foss A,et al. Continuous molecular adsorbent recirculating system treatment in 69 patients listed for liver transplantation. Scand J Gastroenterol, 2015, 50(9): 1127-1134.
23.	Lexmond WS, Van Dael CM, Scheenstra R,et al. Experience with molecular adsorbent recirculating system treatment in 20 children listed for high-urgency liver transplantation. Liver Transpl, 2015, 21(3): 369-380.
24.	Sponholz C, Matthes K, Rupp D,et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure—a prospective, randomised crossover study. Crit Care, 2016, 20: 2.
25.	李蘭娟. 人工肝臨床應用若干進展. 中華肝臟病志, 2005, 13(11): 844-845.
26.	Mitzner SR, Stange J, Klammt S,et al. Albumin dialysis MARS: knowledge from 10 years of clinical investigation. ASAIO J, 2009, 5(5): 498-502.
27.	Saliba F , Samuel D. Artificial liver support: a real step forward. Minerva Med, 2015, 106(1): 35-43.
28.	Hassanein T, Blei AT, Perry W,et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol, 2009, 104(6): 1392-1400.
29.	Leckie P, Tritto G, Mookerjee R,et al. ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther, 2012, 35(6): 696-704.
30.	徐秋仙, 張振綱, 吳亮, 等. 非生物型人工肝對肝衰竭患者療效和預后的影響. 臨床內科雜志, 2015, 32(7): 465-468.
31.	董慶華, 郭利民, 王宇, 等. CAPS 人工肝治療肝衰竭的臨床研究. 實用肝臟病雜志, 2009, 12(5): 352-354.
32.	Parés A, Herrera M, Avilés J,et al. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol, 2010, 53(2): 307-312.
33.	Laleman W, Wilmer A, Evenepoel P,et al. Review article: non-biological liver support in liver failure. Aliment Pharmocol Ther, 2006, 23(3): 351-363.
34.	Rifai K, Ernst T, Kretschmer U,et al. Removal selectivity of prometheus: A new extracorporeal liver support device. World J Gastroenterol, 2006, 12(6): 940-944.
35.	Peter K, Bernd H, Rudolf S,et al.In vivo quantification of liver diaiysis: comparison of albumin dialysis and fractionated plasma separation. J Hepatol, 2005, 43(3): 451-457.
36.	Rodrigues J, Castro SG , Moya B,et al. Liver depurative techniques: a single liver transplantation center experience. Transplant Proc, 2015, 47(4): 996-1000.
37.	Grodzicki M, Kotulski M, Leonowicz D,et al. Results of treatment of acute liver failure patients with use of the prometheus FPSA system. Transplant Proc, 2009, 41(8): 3079-3081.
38.	章莉莎, 趙滿芝, 許東. 少量血漿進行人工肝治療慢加急性肝衰竭的探討. 華中科技大學學報(醫學版), 2015, 44(1): 87-91.
39.	Mitzner S, Klammt S, Stange J,et al. Albumin regeneration in liver support – comparison of different methods. Ther Apher Dial, 2006, 10(2): 108-117.
40.	林文, 黃健, 林松偉, 等. 血漿置換聯合持續靜脈-靜脈血液濾過治療 HBV 相關性肝衰竭患者療效評估. 肝臟, 2015, 20(10): 802-805.
41.	黎代強. 雙重血漿分子吸附系統 (DPMAS) 治療重型肝病新進展. 中國醫學工程, 2015, 23(8): 198-200.
42.	孫潺, 彭程, 揭盛華, 等. 羥乙基淀粉代血漿在人工肝支持系統中治療肝衰竭的應用及安全性. 華中科技大學學報(醫學版), 2013, 42(6): 681-684.

1. ?宋傳芳, 劉冰熔. 急性肝衰竭的綜合治療. 世界華人消化雜志, 2012, 20(33): 3237-3243.
2. 中華醫學會感染病學分會肝衰竭與人工肝學組, 中華醫學會肝病學分會重型肝病與人工肝學組. 肝衰竭診治指南(2012 年版). 實用肝臟病雜志, 2013, 16(3): 210-216.
3. Rademacher S, Oppert M, J?rres A. Artificial extracorporeal liver support therapy in patients with severe liver failure. Expert Rev Gastroenterol Hepatol, 2011, 5(5): 591-599.
4. Kiley JE, Welch hf, Pender JC,et al. Removal of blood ammonia by hemodialysis. Proc Soc Exp Biol Med, 1956, 91(3): 489-490.
5. Norman JC, Saravis CA, Brown ME,et al. Immunological observations in clinical heterologous (xenogeneic) liver perfusions. Surgery, 1966, 60: 179-190.
6. Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future. Gut, 2009, 58(12): 1690-1702.
7. Millis JM, Losanoff JE. Technology insight: liver support systems. Nat Clin Pract Gastroenterol Hepatol, 2005, 9(2): 398-405.
8. Onodera K, Sakata H, Yonekaua M,et al. Artificial liver support at present and in the future. J Artif Organs, 2006, 9(1): 17-28.
9. Aron J, Agarwal B, Daven Port A. Extracorporal support for patients with acute on chronic liver failure . Exp Rev Med Dev, 2016, 10(2): 390-405.
10. Li LJ, Zhang YM, Liu XL,et al. Artificial liver support system in China: a review over the last 30 years. Ther Apher Dial, 2006, 10(2): 160-167.
11. Li LJ, Liu XL, Xu XW,et al. Comparison of plasma exchange with different membrane pore sizes in the treatment of severe viral hepatitis. Ther Apher Dial, 2005, 9(5): 396-401.
12. Larsen FS, Hansen BA, J?rgensen LG,et al. High-volume plasmapheresis and acute liver transplantation in fulminant hepatic failure. Transplant Proc, 1994, 26(3): 1788.
13. Pless G. Artificial and bioartifical liver support. Organogenesis, 2007, 3(1): 20-24.
14. 鄒和群, 劉新宇. 加強血漿凈化技術臨床推廣應用研究. 中華臨床醫師雜志(電子版), 2015, 9(17): 3165-3167.
15. 程芝靈, 孫桂香, 林輝, 等. 血漿置換治療肝衰竭臨床療效和安全性的 Meta 分析. 中國循證醫學雜志, 2015, 15(6): 664-671.
16. 楊文龍, 孫水林, 周錫進, 等. 終末期肝病模型評分與 Child-Turcotte-Pugh 分級對非生物型人工肝治療乙型肝炎相關性肝衰竭患者預測價值的研究. 中華危重癥醫學雜志(電子版), 2016, 9(1): 22-27.
17. 中華傳染病與寄生蟲病學會人工肝學組. 人工肝支持系統治療的操作指南. 中華肝臟病雜志, 2002, 10(5): 329-333.
18. 曾義嵐, 陳竹, 王麗, 等. 人工肝聯合抗病毒治療乙型肝炎相關慢加急性肝功能衰竭患者的療效及影響因素分析. 中國肝臟病雜志(電子版), 2015, 7(4): 26-30.
19. Patzer JF 2nd, Bane SE. Bound solute dialysis. ASAIO J, 2003, 49(3): 271-281.
20. Jalan R, Sen S, Steiner C,et al. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol, 2003, 38(1): 24-31.
21. Inderbitzin D, Muggli B, Ringger A,et al. Molecular absorbent recirculating system for the treatment of acute liver failure in surgical patients. J Gastrointest Surg, 2005, 9(8): 1155-1162.
22. Olin P, Hausken J, Foss A,et al. Continuous molecular adsorbent recirculating system treatment in 69 patients listed for liver transplantation. Scand J Gastroenterol, 2015, 50(9): 1127-1134.
23. Lexmond WS, Van Dael CM, Scheenstra R,et al. Experience with molecular adsorbent recirculating system treatment in 20 children listed for high-urgency liver transplantation. Liver Transpl, 2015, 21(3): 369-380.
24. Sponholz C, Matthes K, Rupp D,et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure—a prospective, randomised crossover study. Crit Care, 2016, 20: 2.
25. 李蘭娟. 人工肝臨床應用若干進展. 中華肝臟病志, 2005, 13(11): 844-845.
26. Mitzner SR, Stange J, Klammt S,et al. Albumin dialysis MARS: knowledge from 10 years of clinical investigation. ASAIO J, 2009, 5(5): 498-502.
27. Saliba F , Samuel D. Artificial liver support: a real step forward. Minerva Med, 2015, 106(1): 35-43.
28. Hassanein T, Blei AT, Perry W,et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol, 2009, 104(6): 1392-1400.
29. Leckie P, Tritto G, Mookerjee R,et al. ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther, 2012, 35(6): 696-704.
30. 徐秋仙, 張振綱, 吳亮, 等. 非生物型人工肝對肝衰竭患者療效和預后的影響. 臨床內科雜志, 2015, 32(7): 465-468.
31. 董慶華, 郭利民, 王宇, 等. CAPS 人工肝治療肝衰竭的臨床研究. 實用肝臟病雜志, 2009, 12(5): 352-354.
32. Parés A, Herrera M, Avilés J,et al. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol, 2010, 53(2): 307-312.
33. Laleman W, Wilmer A, Evenepoel P,et al. Review article: non-biological liver support in liver failure. Aliment Pharmocol Ther, 2006, 23(3): 351-363.
34. Rifai K, Ernst T, Kretschmer U,et al. Removal selectivity of prometheus: A new extracorporeal liver support device. World J Gastroenterol, 2006, 12(6): 940-944.
35. Peter K, Bernd H, Rudolf S,et al.In vivo quantification of liver diaiysis: comparison of albumin dialysis and fractionated plasma separation. J Hepatol, 2005, 43(3): 451-457.
36. Rodrigues J, Castro SG , Moya B,et al. Liver depurative techniques: a single liver transplantation center experience. Transplant Proc, 2015, 47(4): 996-1000.
37. Grodzicki M, Kotulski M, Leonowicz D,et al. Results of treatment of acute liver failure patients with use of the prometheus FPSA system. Transplant Proc, 2009, 41(8): 3079-3081.
38. 章莉莎, 趙滿芝, 許東. 少量血漿進行人工肝治療慢加急性肝衰竭的探討. 華中科技大學學報(醫學版), 2015, 44(1): 87-91.
39. Mitzner S, Klammt S, Stange J,et al. Albumin regeneration in liver support – comparison of different methods. Ther Apher Dial, 2006, 10(2): 108-117.
40. 林文, 黃健, 林松偉, 等. 血漿置換聯合持續靜脈-靜脈血液濾過治療 HBV 相關性肝衰竭患者療效評估. 肝臟, 2015, 20(10): 802-805.
41. 黎代強. 雙重血漿分子吸附系統 (DPMAS) 治療重型肝病新進展. 中國醫學工程, 2015, 23(8): 198-200.
42. 孫潺, 彭程, 揭盛華, 等. 羥乙基淀粉代血漿在人工肝支持系統中治療肝衰竭的應用及安全性. 華中科技大學學報(醫學版), 2013, 42(6): 681-684.

Previous Article
Imaging findings of cystic liver lesions
Next Article
Research progress of pancreas stellate cells in pancreas fibrosis

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Therapy advances of non-biological artificial liver

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content